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Purpose: Investigate near infrared (NIR) acquisition settings fitted for 
different types of particle movement and density. 
Methods: Sample movement in process environment was mimicked 
by designing fast and slow velocity flow devices with NIR probe 
interfacing. In addition, same NIR probe was interfaced with 
fluidizing model particles (pellets) and further, signal from compacted 
pellets was measured. The quality of spectral acquisition with all the 
NIR interfaces was evaluated by performing Principal Component 
Analysis (PCA). 
Results: A defined spectral area linked with the active content was 
found. PCA analysis on that area revealed a clustering given the active 
content of the samples for all the different setups. 
Conclusion: The present study shows different ways to interface NIR 
spectroscopy with production line depending on the sample movement 
and density.  The developed setups enable the real time monitoring of 
samples directly from the production line, giving the opportunity to 
ensure the final product conformity at the end of the manufacturing 
process itself.  
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